---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046110"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:38:46.126924+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement

## Summary
- Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.
- Net loss $13.0M ($1.95 per share) in 2024 vs $13.3M ($4.24 per share) in 2023; operating loss $14.7M.
- Raised $15.0M via private placement, regains Nasdaq compliance and extends runway into 2026.
- FDA agreed on brand name REYOBIQ; orphan drug designation for leptomeningeal metastases in lung cancer.
- Appointed Dr. Michael Rosol as Chief Development Officer; Russell Bradley as President/GM of CNSide Diagnostics.

## SEC filing metadata
- accession: 0000950170-25-046110
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/0000950170-25-046110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/pstv-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046110
- JSON: https://secwatch.observer/filing/0000950170-25-046110.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.